```
1-2
1-3
             (Senate Sponsor - Kolkhorst)
               (In the Senate - Received from the House May 3, 2023;
 1-4
       May 12, 2023, read first time and referred to Committee on Health &
       Human Services; May 21, 2023, reported favorably by the following vote: Yeas 8, Nays 1; May 21, 2023, sent to printer.)
 1-5
 1-6
                                       COMMITTEE VOTE
 1-7
 1-8
                                                           Absent
                                                                          PNV
                                         Yea
                                                  Nay
                                         Χ
 1-9
               Kolkhorst
1-10
1-11
               Perry
               Blanco
1-12
               Hall
                                          Χ
1-13
               Hancock
1-14
               Hughes
                                          Χ
1-15
1-16
               LaMantia
               Miles
1-17
               Sparks
                                          Χ
1-18
1-19
                                   A BILL TO BE ENTITLED
                                            AN ACT
1-20
       relating to the Texas Pharmaceutical Initiative; authorizing fees.
1-21
               BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
       SECTION 1. Subtitle D, Title 10, Government Code, amended by adding Chapter 2177 to read as follows:
1-22
1-24
                   CHAPTER 2177. TEXAS PHARMACEUTICAL INITIATIVE
1-25
                     2177.001. DEFINITIONS. In this chapter:
                            "Board"
1-26
                      (1)
                                      means the governing
                                                                     board
                                                                               of
                                                                                     the
1-27
       initiative.
1-28
                      (2)
                           "Fund" means the Texas Pharmaceutical Initiative
1-29
       fund.
       (3) "Generic biological product" means a biological product approved pursuant to an application under Section 351(k), Public Health Service Act (42 U.S.C. Section 262(k)).

(4) "Generic drug" means a prescription drug approved
1-30
1-31
1-32
1-33
                   to an application under Section 505(j), Federal Food,
1-34
       Drug, and Cosmetic Act (21 U.S.C. Section 355(j)).
1-35
       (5) "Initiative" means the Texas Phantinative established under this chapter.

Sec. 2177.002. TEXAS PHARMACEUTICAL INITIATIVE.
1-36
                                                                       Pharmaceutical
1-37
1-38
               Pharmaceutical Initiative is established to provide
1-39
1-40
       cost-effective access to prescription drugs and other medical
1-41
       supplies for:
1-42
                           employees,
                                          dependents,
                                                          and retirees of public
       higher education systems and institutions;
1-43
                           Employees Retirement System of Texas members;
1-44
       (3) Teacher Retirement System of Texas members;
(4) persons confined by the Texas Department of
Criminal Justice or the Texas Juvenile Justice Department;
(5) recipients of medical assistance under Chapter 32,
1-45
1-46
1-47
1-48
       Human Resources Code; and
1-49
1-50
                     (6) enrollees of the child health plan program under
       Chapter 62, Health and Safety Code.
1-51
1-52
                     A state entity or managed care organization as defined
               (b)
          Chapter 533, Government Code, that provides health benefit plan
1-53
1-54
       coverage to individuals described by Subsection (a) as the entity
1-55
       or managed care organization determines appropriate may elect to
1-56
       provide access to prescription drugs and other medical supplies
       under the initiative.
1-57
1-58
               Sec. 2177.003.
                                   BOARD. (a) The initiative is governed by a
       board composed of:
1-59
1-60
                     (1) the executive commissioner of the Health and Human
```

H.B. No. 4990

1-1

1-61

By:

Bonnen, Frank, Oliverson

Services Commission or the executive commissioner's designee;

H.B. No. 4990

2-1 (2) the executive director of the Employees Retirement 2-2 System of Texas or the executive director's designee;

2-3

2-4

2**-**5 2**-**6

2-7

2-8

2-9

2-10

2-11

2-12

2-13

2-14

2**-**15 2**-**16

2-17

2-18

2-19 2-20 2-21 2-22

2-23

2-24

2**-**25 2**-**26

2-27

2**-**28 2**-**29

2-30

2-31

2-32

2-33

2-34

2-35

2-36

2-37

2-38

2-39

2-40

2-41

2-42

2-43

2-44 2-45 2-46 2-47

2-48

2-49

2**-**50 2**-**51

2**-**52

2-53

2-54

2**-**55 2**-**56

2-57

2**-**58 2**-**59

2-60 2-61 2-62

2-63

2-64

2-65 2-66 2-67

- (3) the executive director of the Teacher Retirement System of Texas or the executive director's designee;
 - (4) three members appointed by the governor;
- (5) one member appointed by the governor from a list of three names submitted by the lieutenant governor;
- (6) one member appointed by the governor from a list of three names submitted by the speaker of the house of representatives; and
- (7) the chancellor of The University of Texas System, or the chancellor's designee, who serves in an ex-officio capacity.
- (b) A vacancy on the board shall be filled in the same manner as the original appointment.
- (c) The appointed board members serve staggered six-year terms.
- (d) The governor shall designate the presiding officer of the board.
- (e) A board member serves without compensation but may be reimbursed for travel and other actual and reasonable expenses incurred in the performance of the member's duties on the board.
- (f) The board is administratively attached to the Health and Human Services Commission.
 - Sec. 2177.004. DUTIES OF BOARD. (a) The board shall:
- (1) develop and implement the initiative and related programs established by this chapter;
- (2) establish procedures and policies for the administration of the initiative;
- (3) establish procedures to document compliance by board members and personnel with applicable laws governing conflicts of interest;
- (4) ensure that a program or entity created under this chapter meets any applicable licensing or accreditation requirements under state or federal law; and
- (5) recommend rules necessary to implement this chapter for adoption by the executive commissioner of the Health and Human Services Commission.
- (b) To carry out the purposes of this chapter the board may:

 (1) execute contracts and other instruments and conduct all activities the board determines necessary for those purposes;
- (2) authorize one or more board members to execute contracts and other instruments on behalf of the board;
- (3) establish a committee or other similar entity to exercise powers delegated by the board and exercise any other administrative duties or powers as the board considers necessary;
- (4) employ an executive director and necessary personnel to provide administrative support; and
- (5) award grants to public or private persons to implement the initiative.
- implement the initiative.

 (c) The board may refrain from establishing a program or entity under this chapter if the board determines that establishment is not feasible with current resources or considering other state-funded programs.
- (d) A contract or agreement executed under this chapter must comply with Chapter 2254, if applicable.
- Sec. 2177.005. PHARMACY BENEFIT MANAGER. (a) The board shall contract for a statewide pharmacy benefit manager, as provided by Subchapter H, Chapter 2158, to provide cost-effective prescription drugs through the establishment of a pharmacy network to state entities served by the initiative.
- (b) The pharmacy benefit manager shall provide pricing transparency, a pass-through of all rebates and fees, and fair and equitable pricing to a pharmacy that participates in the pharmacy benefit manager's pharmacy network.
- benefit manager's pharmacy network.

 (c) The pharmacy benefit manager shall contract with appropriate persons to:
- 2-68 (1) provide an evidence-based benefit design, a prior authorization process, and a new drug review process; and

H.B. No. 4990

(2) partner with suppliers, pharmaceutical manufacturers, and group purchasing organizations for competitive 3-1 3-2 acquisition of prescription drugs and medical supplies. 3-3

Sec. 2177.006. DISTRIBUTION OF PRESCRIPTION DRUGS AND MEDICAL SUPPLIES. (a) The board shall establish and implement a central service center and an associated network of satellite distribution facilities to provide prescription drugs and medical supplies to individuals described by Section 2177.002 for state entities that elect to participate in the initiative. The center

be constructed to withstand extreme weather conditions, natural disasters, and power outages;

(2) be capable of providing disaster preparedness and response resources statewide; and

order pharmacy and specialty (3) include a mail

pharmacy.

must:

3 - 43-5 3**-**6

3-7 3-8

3-9 3-10

3**-**11

3-12 3-13

3-14

3-15

3-16

3-17

3**-**18

3-19

3-20

3-21 3-22

3-23

3-24

3-25 3-26 3-27

3-28

3-29 3-30 3-31

3-32

3-33

3-34 3-35 3-36 3-37

3-38

3-39 3-40 3-41 3-42

3-43

3-44 3-45 3-46 3-47 3-48

3-49 3-50 3-51 3**-**52

3-53

3-54 3**-**55 3**-**56 3-57

3-58

3-59

3-60 3-61

3-62 3-63

3-64

3**-**65 3**-**66

3-67

3-68 3-69

(b) The central service center may assess an inventory storage charge, transaction fees, or other fees on persons obtaining prescription drugs and medical supplies from the center to support the center's distribution and other operational costs, including overhead and margin.

(c) The mail order and specialty pharmacy established in the central service center may assess delivery and handling fees on

persons receiving prescription drugs from the pharmacy.

Sec. 2177.007. PHARMACEUTICAL ADVANCED PREPARATION FACILITY. (a) The board shall establish a pharmaceutical advanced preparation facility to serve as an outsourcing facility in compliance with Section 503B, Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 353b), to:

(1) manufacture and provide compounded drugs;
(2) provide chimeric antigen receptor

T-cell treatment and other gene therapies, including precision medicine;

(3) provide advanced laboratories for quality control, preparation, and compounding of drugs in support of innovative therapeutics and drug research.

(b) The pharmaceutical advanced preparation facility shall operated by an organization established by the board that is exempt from federal income taxation under Section 501(a), Internal Revenue Code of 1986, by being listed as an exempt entity under Section 501(c)(3) of that code.

(c) The pharmaceutical advanced preparation facility may

charge fees to persons to whom the facility provides drugs,

treatment, supplies, or other services to support the operational costs of the facility, including overhead and margin.

Sec. 2177.008. ADVANCED HEALTH CARE COST AND CLAIMS ANALYTIC SERVICES. (a) The board shall contract with a person to provide advanced health care claims analytics software to support the programs and entities created by this chapter and to support population health research.

(b) The board shall develop criteria for the evaluation of

applications or proposals submitted by a person seeking to contract

with the board under this section.

Sec. 2177.009. GENERIC BIOLOGICAL PRODUCT AND GENERIC DRUG MANUFACTURING FACILITY. (a) The board may enter into an agreement with a person to establish a facility that manufactures generic biological products and generic drugs in compliance with any requirements of the federal Food and Drug Administration. entering into the agreement, the board shall prioritize savings and

access to affordable medications.
(b) The board shall develop criteria for the evaluation of applications or proposals submitted by a person seeking to contract

with the board under this section.

Sec. 2177.010. CONFIDENTIALITY OF CERTAIN INFORMATION. Any information received by the board, a program or entity created by this chapter, a state entity participating in the initiative, or a contractor or agent of the board that if directly or indirectly disclosed is likely to compromise the financial, competitive, or proprietary nature of the information, is confidential and not

H.B. No. 4990 subject to disclosure under Chapter 552. 4-1 Sec. 2177.011. TEXAS PHARMACEUTICAL INITIATIVE FUND. 4-2 The Texas Pharmaceutical Initiative fund is created as a trust fund 4-3 4-4 to be held by the comptroller outside the state treasury. 4-5 The fund consists of: 4-6 money from gifts, grants, and donations to the (1)4-7 fund; 4-8 additional legislative appropriations of any money for the purposes of the fund; and 4-9 4-10 4-11 (3) interest, dividends, and other income of the fund. The board may only use money in the fund to carry out the 4-12 purposes of this chapter. 4-13 The board shall develop procedures for administration and approval of expenditures of the fund. 4-14 4**-**15 4**-**16 Sec. 2177.012. FUNDING. The board may accept gifts, grants, and donations from any public or private source for the 4-17 purpose of carrying out this chapter. 4-18 Sec. 2177.013. ANNUAL REPORT. Not later than December 31 of 4-19 the board shall submit to the legislature a written year, 4-20 4-21 report on: (1)the activities and objectives of the initiative; 4-22 (2) any cost savings for state entities that 4-23 participate in the initiative; and 4-24 for legisl<u>ative or other</u> (3) any recommendations 4-25 action. <u>Sec. 2177.014.</u> 4-26 SUNSET The PROVISION. board and the 4-27 initiative established under this chapter are subject to Chapter 4-28 325, Government Code (Texas Sunset Act). Unless continued in 4-29 existence as provided by that chapter, the board and the initiative

are abolished and this chapter expires September 1, 2035.
SECTION 2. This Act takes effect immediately if it receives a vote of two-thirds of all the members elected to each house, as provided by Section 39, Article III, Texas Constitution. If this Act does not receive the vote necessary for immediate effect, this

Act takes effect September 1, 2023.

* * * * * 4-36

4-30 4-31 4-32

4-33 4-34

4-35